The MoU was signed by Dr. Asma Al Mannaei, Executive Director of the Research and Innovation Center at the Department of Health – Abu Dhabi(DoH), Fra...
The STARBURST study (ClinicalTrials.gov Identifier: NCT05563272) is a prospective, open label Phase II "basket" study to investigate CAIX expression in pat...
Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response (remission) rate and a median duration of response of 1...
CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, announced that its CE...
Safety data encouraging with no graft-versus-host-disease and no neurotoxicity Updated data highlighted in podium presentation at the 17th International...
Genomill, a pioneering precision diagnostics company, brings its cutting-edge Geno1® platform to the collaboration. Genomill's proprietary and patented...
Future Fields, a pioneering biotechnology company that has built the world’s first synthetic biology system to use fruit flies for recombinant protei...
There are multiple drugs available to treat breast cancer. Most patients become drug resistant, meaning that the cancer cells aren't responding to the drug...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its variant interpretation and reporting software, QIAGEN Clinical Insight (QCI) In...
SciTech Development today announced it has closed a $2.73M funding round, led by several prominent life science investors to advance clinical trials for No...
Over the past several years, management has initiated discussions with potential strategic collaborators to provide the resources to advance PRP into clini...
Gives Nordic Nanovector access to highly promising new technology that enables the development and production of radionuclides for radioimmunoconjugate-b...
CID is a common and often debilitating toxicity affecting up to 90% of patients receiving chemotherapy. CID can cause dehydration, electrolyte imbalance, m...
The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerability Positive clinical responses were repor...
© 2025 Biopharma Boardroom. All Rights Reserved.
